Generex Biotechnology (OTCMKTS:GNBT) Stock Crosses Above 200-Day Moving Average of $0.29

Generex Biotechnology Co. (OTCMKTS:GNBT)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.29 and traded as high as $0.29. Generex Biotechnology shares last traded at $0.29, with a volume of 526,119 shares changing hands.

The company has a current ratio of 0.04, a quick ratio of 0.03 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $33.61 million, a P/E ratio of -0.66 and a beta of -2.64. The business’s fifty day moving average price is $0.29 and its 200-day moving average price is $0.29.

Generex Biotechnology (OTCMKTS:GNBT) last posted its quarterly earnings data on Wednesday, March 17th. The company reported ($0.08) earnings per share (EPS) for the quarter. Generex Biotechnology had a negative return on equity of 1,712.86% and a negative net margin of 1,722.93%.

About Generex Biotechnology (OTCMKTS:GNBT)

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer.

See Also: Swap

Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.